Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Net Income for 16 consecutive years, with -$163.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 68.83% to -$163.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$137.0 million through Dec 2025, down 39.63% year-over-year, with the annual reading at -$137.1 million for FY2025, 39.7% down from the prior year.
  • Net Income hit -$163.4 million in Q4 2025 for Ironwood Pharmaceuticals, down from $40.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $391.3 million in Q2 2021 to a low of -$1.1 billion in Q2 2023.
  • Historically, Net Income has averaged -$24.9 million across 5 years, with a median of $30.4 million in 2022.
  • Biggest five-year swings in Net Income: plummeted 5462.3% in 2024 and later skyrocketed 2846.74% in 2025.
  • Year by year, Net Income stood at $41.4 million in 2021, then skyrocketed by 177.23% to $114.6 million in 2022, then crashed by 101.52% to -$1.7 million in 2023, then tumbled by 5462.3% to -$96.8 million in 2024, then plummeted by 68.83% to -$163.4 million in 2025.
  • Business Quant data shows Net Income for IRWD at -$163.4 million in Q4 2025, $40.1 million in Q3 2025, and $23.6 million in Q2 2025.